The FDA Group's Insider Newsletter
Subscribe
Sign in
Share this discussion
Small Lots, Big Risks: Rethinking Statistical Sampling in Biopharma
insider.thefdagroup.com
Copy link
Facebook
Email
Note
Other
Small Lots, Big Risks: Rethinking Statistical…
The FDA Group
Aug 29
2
Share this post
Small Lots, Big Risks: Rethinking Statistical Sampling in Biopharma
insider.thefdagroup.com
Copy link
Facebook
Email
Note
Other
Watch now (19 mins) | We sat down with Gary Ritchie to learn why N + 1 doesn't always add up.
Read →
Comments
Share
Share
Copy link
Facebook
Email
Note
Other
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
Small Lots, Big Risks: Rethinking Statistical Sampling in Biopharma
Small Lots, Big Risks: Rethinking Statistical…
Small Lots, Big Risks: Rethinking Statistical Sampling in Biopharma
Watch now (19 mins) | We sat down with Gary Ritchie to learn why N + 1 doesn't always add up.